© 2019 by ATXA Therapeutics Limited.

Dublin, Ireland

Home  |  About Us  |  News  |  Contact Us

Follow us on:

  • LinkedIn Social Icon
  • Facebook Social Icon
  • Twitter Social Icon

NEWS & INSIGHTS

November 13, 2018

DUBLIN, IRELAND – November 13, 2018 – ATXA Therapeutics Ltd CEO, Dr. Ivan Coulter will today attend the Biotech and Money Inv€$tival Showcase conference in London.  The Biotech and Money Inv€$tival showcase organized by LSX and partnered with Jefferies, connects c...

October 26, 2018

DUBLIN, IRELAND – October 26, 2018 – ATXA Therapeutics (“ATXA”), a pharmaceutical company focused on the discovery and development of new therapeutic drugs in heart and lung disease area, has today announced the appointment of Ivan Coulter, PhD, M.B.A., as Chief Execut...

September 10, 2018

DUBLIN, IRELAND – September 10, 2018 – From 10-11 September 2018, the European Innovation Council (EIC) will host more than 600 top SMEs, researchers, and entrepreneurs from the most relevant innovation funding programmes of the European Union (i.e. SME Instrument, FTI...

May 15, 2018

DUBLIN, IRELAND – May 15, 2018 – ATXA Therapeutics Limited, an Irish company developing novel therapeutic drugs for the treatment of Pulmonary Arterial Hypertension (PAH) and for other related cardiovascular conditions, has secured €2.5 million funding under the Europe...

May 10, 2018

DUBLIN, IRELAND – May 10, 2018 – Founder & Chief Scientific Officer of ATXA Therapeutics, Prof. Therese Kinsella, attended a reception with the President of Ireland Michael D. Higgins and his wife Sabina Higgins, at Áras an Uachtaráin on Friday, May 4th, 2018.

The recep...

April 3, 2018

DUBLIN, IRELAND – April 3, 2018 – ATXA Therapeutics Limited Founder and Chief Scientific Officer, Prof. Therese Kinsella, PhD, MRIA, will be attending the 2018 Medtech Strategist Innovation Summit in Dublin, Ireland, from April 17-19, 2018. The event will take place at...

March 8, 2018

DUBLIN, IRELAND – March 8, 2018 – ATXA Therapeutics Limited, an early-stage Irish biopharmaceutical company focused on clinical development of novel small molecule drugs to treat Pulmonary Arterial Hypertension (PAH), is pleased to announce that the United States Food...

February 23, 2018

DUBLIN, IRELAND – February 23, 2018 – ATXA Therapeutics Limited, an early-stage Irish biopharmaceutical company focused on clinical development of novel small molecule drugs to treat Pulmonary Arterial Hypertension (PAH), announced today that the European Medicines Age...

February 2, 2018

DUBLIN, IRELAND – February 2, 2018 – ATXA Therapeutics Limited, an early-stage Irish biopharmaceutical company focused on clinical development of novel small molecule drugs to treat Pulmonary Arterial Hypertension (PAH), announced today that its Founder and Chief Scien...

Please reload

Recent Posts

September 30, 2019

Please reload

Archive
Please reload

Search By Tags